Showing results (691-700 of 3,978) with videos related to

Sort By:
Pageof 398
European Journal of Heart Failure|October 18, 2020
Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension studyThibaud Damy, Pablo Garcia-Pavia, Mazen Hanna, et al.
European Journal of Heart Failure|July 6, 2022
Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan: insights from the VICTORIA trialMichele Senni, Wendimagegn G Alemayehu, David Sim, et al.
European Journal of Heart Failure|July 6, 2022
Baseline clinical characteristics of heart failure patients with reduced ejection fraction enrolled in the BUDAPEST-CRT Upgrade trialBéla Merkely, László Gellér, Endre Zima, et al.
European Journal of Heart Failure|July 6, 2022
Guideline-directed medical therapy in patients undergoing transcatheter edge-to-edge repair for secondary mitral regurgitationSatoshi Higuchi, Mathias Orban, Marianna Adamo, et al.
European Journal of Heart Failure|July 2, 2022
A global perspective on the management and outcomes of peripartum cardiomyopathy: a systematic review and meta-analysisJulian Hoevelmann, Mark E Engel, Elani Muller, et al.
European Journal of Heart Failure|July 2, 2022
Progression of echocardiographic parameters and prognosis in transthyretin cardiac amyloidosisLiza Chacko, Nina Karia, Lucia Venneri, et al.
European Journal of Heart Failure|July 2, 2022
Catheter ablation for patients with atrial fibrillation and heart failure: insights from the Swedish Heart Failure RegistryGesa von Olshausen, Lina Benson, Ulf Dahlström, et al.
European Journal of Heart Failure|December 11, 2019
Initiation of sacubitril/valsartan shortly after hospitalisation for acutely decompensated heart failure in patients with newly diagnosed (de novo) heart failure: a subgroup analysis of the TRANSITION studyMichele Senni, Rolf Wachter, Klaus K Witte, et al.
European Journal of Heart Failure|June 17, 2022
Baroreflex activation therapy with the Barostim™ device in patients with heart failure with reduced ejection fraction: a patient level meta-analysis of randomized controlled trialsAndrew J S Coats, William T Abraham, Michael R Zile, et al.
European Journal of Heart Failure|November 30, 2020
Design of a prospective patient-level pooled analysis of two parallel trials of empagliflozin in patients with established heart failureMilton Packer, Javed Butler, Gerasimos Filippatos, et al.
Pageof 398